🚀 VC round data is live in beta, check it out!
Nanexa Valuation Multiples
Discover revenue and EBITDA valuation multiples for Nanexa and similar public comparables like Citius Oncology, Fortress Biotech, XBiotech, Synthaverse and more.
Nanexa Overview
About Nanexa
Nanexa AB is a pharmaceutical company developing injectable drug products based on the proprietary drug delivery system PharmaShell - the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. The company develops its products and also has collaboration agreements with several pharma companies, among others AstraZeneca. Geographically, the company derives maximum revenue from Nordic countries.
Founded
2007
HQ
Employees
17
Website
Sectors
Financials (FY)
EV
$72M
Nanexa Financials
Nanexa reported last fiscal year revenue of $4M and EBITDA of $452K.
In the same fiscal year, Nanexa generated $6M in gross profit, $452K in EBITDA, and had net loss of ($1M).
Nanexa P&L
In the most recent fiscal year, Nanexa reported revenue of $4M and EBITDA of $452K.
Nanexa expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $4M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $6M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 155% | XXX | XXX | XXX |
| EBITDA | — | XXX | $452K | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 12% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (23%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($1M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (32%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Nanexa Stock Performance
Nanexa has current market cap of $76M, and enterprise value of $72M.
Market Cap Evolution
Nanexa's stock price is $0.41.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $72M | $76M | -1.6% | XXX | XXX | XXX | $-0.01 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNanexa Valuation Multiples
Nanexa trades at 18.3x EV/Revenue multiple, and 158.7x EV/EBITDA.
Nanexa Financial Valuation Multiples
As of April 18, 2026, Nanexa has market cap of $76M and EV of $72M.
Equity research analysts estimate Nanexa's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Nanexa has a P/E ratio of (61.7x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $76M | XXX | $76M | XXX | XXX | XXX |
| EV (current) | $72M | XXX | $72M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 18.3x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 158.7x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (79.5x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 11.8x | XXX | XXX | XXX |
| P/E | — | XXX | (61.7x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (25.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Nanexa Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Nanexa Margins & Growth Rates
Nanexa's revenue in the last fiscal year grew by 48%.
Nanexa's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.4M for the same period.
Nanexa Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 48% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 12% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (130%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 38% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 178% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Nanexa Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Nanexa | XXX | XXX | XXX | XXX | XXX | XXX |
| Citius Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| Fortress Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| XBiotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Synthaverse | XXX | XXX | XXX | XXX | XXX | XXX |
| IBT | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Nanexa M&A Activity
Nanexa acquired XXX companies to date.
Last acquisition by Nanexa was on XXXXXXXX, XXXXX. Nanexa acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Nanexa
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialNanexa Investment Activity
Nanexa invested in XXX companies to date.
Nanexa made its latest investment on XXXXXXXX, XXXXX. Nanexa invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Nanexa
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Nanexa
| When was Nanexa founded? | Nanexa was founded in 2007. |
| Where is Nanexa headquartered? | Nanexa is headquartered in Sweden. |
| How many employees does Nanexa have? | As of today, Nanexa has over 17 employees. |
| Is Nanexa publicly listed? | Yes, Nanexa is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of Nanexa? | Nanexa trades under NANEXA ticker. |
| When did Nanexa go public? | Nanexa went public in 2015. |
| Who are competitors of Nanexa? | Nanexa main competitors are Citius Oncology, Fortress Biotech, XBiotech, Synthaverse. |
| What is the current market cap of Nanexa? | Nanexa's current market cap is $76M. |
| What is the current revenue of Nanexa? | Nanexa's last fiscal year revenue is $4M. |
| What is the current EV/Revenue multiple of Nanexa? | Current revenue multiple of Nanexa is 18.3x. |
| Is Nanexa profitable? | No, Nanexa is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.